AMRUTANJAN:NSE-Amrutanjan Health Care Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 727.35

Change

0.00 (0.00)%

Market Cap

INR 21.26B

Volume

0.01M

Avg Analyst Target

N/A

Avg User Target

INR
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


AMRUTANJAN Stock Forecast & Price:
Based on the Amrutanjan Health Care Limited stock forecasts from 0 analysts, the average analyst target price for Amrutanjan Health Care Limited is not available over the next 12 months. Amrutanjan Health Care Limited’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Amrutanjan Health Care Limited is Slightly Bullish , which is based on 9 positive signals and 4 negative signals. At the last closing, Amrutanjan Health Care Limited’s stock price was INR 727.35. Amrutanjan Health Care Limited’s stock price has changed by -0.38% over the past week, -0.23% over the past month and -12.03% over the last year.

About Amrutanjan Health Care Limited (AMRUTANJAN:NSE)

Amrutanjan Health Care Limited manufactures, supplies, and sells ayurvedic pain balms, non-alcoholic beverages, and sanitary napkins. The company operates through OTC Products, Beverages, and Others segments. It provides pain management products comprising pain balms and roll-ons ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-24 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

N/A

INR2,214.46B 56.97 28.30
DIVISLAB:NSE Divi's Laboratories Limited

N/A

INR967.00B 31.09 22.83
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

N/A

INR687.17B 23.16 12.75
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

N/A

INR516.97B 64.59 24.74
ALKEM:NSE Alkem Laboratories Limited

N/A

INR389.52B 29.84 22.75
ZYDUSLIFE:NSE Zydus Lifesciences Limited

N/A

INR363.08B 16.91 10.46
AUROPHARMA:NSE Aurobindo Pharma Limited

N/A

INR305.68B 12.75 7.14
LUPIN:NSE Lupin Limited

N/A

INR298.20B 25.10 -85.29
LAURUSLABS:NSE Laurus Labs Limited

N/A

INR281.49B 33.74 20.07
PEL:NSE Piramal Enterprises Limited

N/A

INR228.60B 12.21 9.19

ETFs Containing AMRUTANJAN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -22.33% 46% F 23% F
Dividend Return 0.38% 28% F 24% F
Total Return -21.95% 44% F 22% F
Trailing 12 Months  
Capital Gain -12.03% 67% D+ 29% F
Dividend Return 0.56% 48% F 32% F
Total Return -11.47% 68% D+ 28% F
Trailing 5 Years  
Capital Gain 148.39% 81% B- 81% B-
Dividend Return 4.59% 71% C- 58% F
Total Return 152.98% 79% C+ 82% B-
Average Annual (5 Year Horizon)  
Capital Gain 34.95% 70% C- 72% C-
Dividend Return 0.60% 64% D 47% F
Total Return 35.55% 68% D+ 72% C-
Risk Return Profile  
Volatility (Standard Deviation) 35.17% 79% C+ 77% C+
Risk Adjusted Return 101.09% 94% A 98% A+
Market Capitalization 21.26B 53% F 61% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 35.99 28% F 31% F
Price/Book Ratio 8.02 14% F 13% F
Price / Cash Flow Ratio 40.73 24% F 19% F
EV/EBITDA 22.89 21% F 23% F
Management Effectiveness  
Return on Equity 27.96% 92% A- 89% B+
Return on Invested Capital 21.76% 89% B+ 89% B+
Return on Assets 15.16% 92% A- 94% A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield 0.99% 60% D- 56% F
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.71 56% F 61% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.